Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 287

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 12
Chunk 287
---
    7,245 Reversal of expected credit losses      1,689,412   - Others      59,405   42,093 TOTAL OTHER INCOME      2,072,473   486,036              OPERATING EXPENSES            Sales and marketing      (2,030,684)  (596,858)Research and development      (47,511)  (54,982)General and administrative (including $1,969 and nil of rental expenses to related party for theyears ended December 31, 2024 and 2023, respectively)      (1,973,968)  (2,442,855)Provision for expected credit losses       (883,533)  (1,314,427)TOTAL OPERATING EXPENSES      (4,935,696)  (4,409,122)             LOSS FROM OPERATIONS      (1,573,702)  (2,593,588)             FINANCE COSTS      (21,146)  (13,929)             LOSS BEFORE TAX      (1,594,848)  (2,607,517)             Tax expense:            Deferred tax      12,305   17,359 Income tax      (15,799)  (38,885)Tax expense      (3,494)  (21,526)             NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS      $(1,598,342) $(2,629,043)             Other comprehensive income/(loss):            Foreign currency translation gain/(loss)      122,294   (268,232)             COMPREHENSIVE LOSS     $(1,476,048) $(2,897,275)             Earnings per share - Basic and diluted      (0.090)  (0.166)Weighted average number of common stocks outstanding, Basic and Diluted       17,818,483  15,875,455 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected